Summary
Bayer’s Rimobolan 100 mg/mL was submitted by DEVONPCT@PROTONMAIL.COM for independent testing to confirm its potency and label claim. The analysis, performed by Janoshik Analytical, revealed a measured concentration of 101.76 mg/mL Methenolone Enanthate, representing an accuracy of 101.76% of the label claim and a variance of +1.76%.
The sample, identified by batch number 1, was received on 6 August 2024, with the analysis completed on 15 August 2024. These results suggest that the product meets its label claim with a slight overage, indicative of strong quality control. However, as the sample was submitted by a reseller, it is crucial to emphasize that such results might not fully represent the consistency across other batches. Independent validation through third-party testing remains essential for comprehensive quality assurance.
This report is published to promote transparency, harm reduction, and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Bayer
- Product Name: Rimobolan 100 mg/mL
- Active Ingredient: Methenolone Enanthate
- Batch Number: 1
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #46714
- Testing Ordered: 1 August 2024
- Sample Received: 6 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: DEVONPCT@PROTONMAIL.COM (Reseller)
- Analysis Paid For By: DEVONPCT@PROTONMAIL.COM
Testing Results
- Specification (Label Claim): 100 mg/mL
- Measured Concentration: 101.76 mg/mL
- Accuracy: 101.76%
- Variance: +1.76%
Verification Details
- Verification URL: https://janoshik.com/tests/46714_VEN5WFSXNTMU
- Originally Published: https://thinksteroids.com/community/posts/3322770/
Evaluation of Reseller-Submitted Testing
Although this analysis confirms the product’s high accuracy, it is important to note that reseller-submitted samples may not fully reflect the product’s consistency. Resellers may select high-quality batches for testing, potentially biasing the results. Independent, third-party testing across multiple batches is strongly recommended to ensure reliability and consistency.
Conclusion
The analysis confirms that Bayer’s Rimobolan 100 mg/mL slightly exceeds its label claim, with a measured concentration of 101.76 mg/mL. This indicates a high level of quality control for this batch. However, further testing is recommended to ensure consistency across the product line. This report serves as an educational tool to support harm reduction efforts and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
